Targeting caspases in cancer therapeutics

Retinoids in Pediatric Onco-Hematology: the Model of Acute Promyelocytic Leukemia and Neuroblastoma

(2012) Riccardo Masetti et al.   ADVANCES IN THERAPY

Myelodysplastic Syndromes: Therapy and Outlook

(2012) Roger M. Lyons   AMERICAN JOURNAL OF MEDICINE

Synthesis and biological evaluation of a series of podophyllotoxins derivatives as a class of potent antitubulin agents

(2012) Yingqian Liu et al.   BIOORGANIC & MEDICINAL CHEMISTRY

New developments in castrate-resistant prostate cancer

(2012) N. Shore et al.   BJU INTERNATIONAL

Urologists and oncologists: adapting to a new treatment paradigm in castration-resistant prostate cancer (CRPC)

(2012) A. Oliver Sartor et al.   BJU INTERNATIONAL

Apoptosis-Modulating Drugs for Improved Cancer Therapy

(2012) M. Ocker et al.   EUROPEAN SURGICAL RESEARCH

Modeling Prostate Cancer in Mice: Limitations and Opportunities

(2012) P. J. Hensley et al.   JOURNAL OF ANDROLOGY

JR6, a new compound isolated from Justicia procumbens, induces apoptosis in human bladder cancer EJ cells through caspase-dependent pathway

(2012) Xiao-Li He et al.   JOURNAL OF ETHNOPHARMACOLOGY

YM155 Reverses Cisplatin Resistance in Head and Neck Cancer by Decreasing Cytoplasmic Survivin Levels

(2012) B. Kumar et al.   MOLECULAR CANCER THERAPEUTICS

A Perspective on Mammalian Caspases as Positive and Negative Regulators of Inflammation

(2012) Seamus J. Martin et al.   MOLECULAR CELL

Phase I study of terameprocol in patients with recurrent high-grade glioma

(2012) S. A. Grossman et al.   NEURO-ONCOLOGY

Survivin splice variants are not essential for mitotic progression or inhibition of apoptosis induced by doxorubicin and radiation

(2012) Naduparambil Jacob et al.   OncoTargets and Therapy

Survivin in Solid Tumors: Rationale for Development of Inhibitors

(2012) David N. Church et al.   Current Oncology Reports

YM155, a novel survivin suppressant, enhances taxane-induced apoptosis and tumor regression in a human Calu 6 lung cancer xenograft model

(2011) Takahito Nakahara et al.   ANTI-CANCER DRUGS

Programmed Cell Death in Animal Development and Disease

(2011) Yaron Fuchs et al.   CELL

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Significant Biological Role of Sp1 Transactivation in Multiple Myeloma

(2011) M. Fulciniti et al.   CLINICAL CANCER RESEARCH

Antitumor Activity of YM155, a Selective Small-Molecule Survivin Suppressant, Alone and in Combination with Docetaxel in Human Malignant Melanoma Models

(2011) Kentaro Yamanaka et al.   CLINICAL CANCER RESEARCH

The Two Faces of Interferon-  in Cancer

(2011) M. R. Zaidi et al.   CLINICAL CANCER RESEARCH

Anoikis Disruption of Focal Adhesion-Akt Signaling Impairs Renal Cell Carcinoma

(2011) Shinichi Sakamoto et al.   EUROPEAN UROLOGY

Antisense Inhibition of Survivin Expression as a Cancer Therapeutic

(2011) R. A. Carrasco et al.   MOLECULAR CANCER THERAPEUTICS

Caspase 8 and maspin are downregulated in breast cancer cells due to CpG site promoter methylation

(2010) Yanyuan Wu et al.   BMC CANCER

Phase I study of LY2181308, an antisense oligonucleotide against survivin, in patients with advanced solid tumors

(2010) M. Tanioka et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

The Inflammasomes

(2010) Kate Schroder et al.   CELL

Targeting anoikis resistance in prostate cancer metastasis

(2010) Shinichi Sakamoto et al.   MOLECULAR ASPECTS OF MEDICINE

Global Targeting of Subcellular Heat Shock Protein-90 Networks for Therapy of Glioblastoma

(2010) M. D. Siegelin et al.   MOLECULAR CANCER THERAPEUTICS

Genomic instability — an evolving hallmark of cancer

(2010) Simona Negrini et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Adeno-Associated Virus Harboring Fusion Gene NT4-Ant-Shepherdin Induce Cell Death in Human Lung Cancer Cells

(2009) Tang Xiaojiang et al.   CANCER INVESTIGATION

Endogenous Tumor Suppression Mediated by PTEN Involves Survivin Gene Silencing

(2009) M. Guha et al.   CANCER RESEARCH

Phase I Study of YM155, a Novel Survivin Suppressant, in Patients with Advanced Solid Tumors

(2009) T. Satoh et al.   CLINICAL CANCER RESEARCH

Multicenter Phase II Trial of YM155, a Small-Molecule Suppressor of Survivin, in Patients With Advanced, Refractory, Non–Small-Cell Lung Cancer

(2009) Giuseppe Giaccone et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

(2009) Pierre Fenaux et al.   LANCET ONCOLOGY

DNA hypomethylation in cancer cells

(2009) Melanie Ehrlich   Epigenomics

Radiosensitizing Effect of YM155, a Novel Small-Molecule Survivin Suppressant, in Non-Small Cell Lung Cancer Cell Lines

(2008) T. Iwasa et al.   CLINICAL CANCER RESEARCH

SPC3042: a proapoptotic survivin inhibitor

(2008) J. B. Hansen et al.   MOLECULAR CANCER THERAPEUTICS

Interplay among BRCA1, SIRT1, and Survivin during BRCA1-Associated Tumorigenesis

(2008) Rui-Hong Wang et al.   MOLECULAR CELL

Chemically synthesized human survivin does not inhibit caspase-3

(2008) Changqing Li et al.   PROTEIN SCIENCE

Apoptin: Therapeutic Potential of an Early Sensor of Carcinogenic Transformation

(2007) Claude Backendorf et al.   Annual Review of Pharmacology and Toxicology